FDA reviewers voice concern about side effects of belatacept

02/25/2010 | Los Angeles Times (tiered subscription model)

Bristol-Myers Squibb's kidney transplant drug belatacept extended survival better than older treatments, FDA reviewers said, but it also appeared to cause a higher rate of severe kidney rejection and neurological disease. A panel of experts is scheduled to evaluate the drug's safety and efficacy next week.

View Full Article in:

Los Angeles Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA